Meet the Board

Dr David Mazzo

Dr David Mazzo

Chairman of the Board
Dr Stephen Snowdy

Dr Stephen Snowdy

Chief Executive Officer and Executive Director
Mr Brian Lane

Mr Brian Lane

Chief Financial Officer
Mr Tony Sommer, Jr.

Mr Tony Sommer, Jr.

Senior VP Sales and Marketing
Christi Van Heek

Christi Van Heek

Non-executive Director
Jean Franchi

Jean Franchi

Non-executive Director
Zita Peach

Zita Peach

Non-executive Director
Tom Dooley

Tom Dooley

Non-executive Director
Andrew Silverberg

Andrew Silverberg

Non-executive Director

Dr David Mazzo

Chairman of the Board

Dr. David Mazzo is a highly accomplished and experienced life sciences executive and board director with almost 40 years of experience in managing medical device and pharmaceutical companies.

 

Dr. Mazzo is currently President, CEO and Executive Director of Caladrius Biosciences, Inc. (NASDAQ: CLBS). He also serves on the boards of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT), and Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA). Previously, Dr. Mazzo served as CEO and Executive Director of Regado Biosciences, Inc., where, among other accomplishments, he led Regado’s IPO.

 

Prior to leading Regado, Dr. Mazzo was CEO and Executive Director of Aeterna Zentaris (NASDAQ: AEZS, TSX: AEZS), and of Chugai Pharma USA, LLC, the U.S. subsidiary of Japan’s Chugai Pharmaceuticals Co. Ltd. (TYO: 4519), a member of the Roche group (SWX:RO).  Dr. Mazzo has also had a distinguished international career leading pharmaceutical development for Rhone-Poulenc Rorer and Hoechst Marion Roussel culminating in his position as Senior Vice President of Development Operations for Schering-Plough Research Institute.

 

Dr. Mazzo’s academic training and early career were in analytical chemistry.  He received his Ph.D. degree in Analytical Chemistry from the University of Massachusetts Amherst, and completed a research fellowship at the Ecole Polytechnique Federale de Lausanne in Switzerland.  He earned a BA in the Honors program (interdisciplinary humanities) and a BS in chemistry at Villanova University.

Dr Stephen Snowdy

Chief Executive Officer and Executive Director

Dr Snowdy initially joined VTI as Chairman in May 2009, and he has been Chief Executive Officer since June 2013. He has 15 years of experience in life science venture investing and executive management.  Dr Snowdy holds a PhD in Neurobiology and an MBA from the University of North Carolina, as well as a Bachelor of Science (major in chemistry) from the University of Florida.

Mr Brian Lane

Chief Financial Officer

Brian has 30 years of experience in financial operations and management. He was the CFO of OnePath, and was previously the controller for PRGX Global (NASDAQ:PRGX). Brian has held senior finance roles in other companies in financial services, franchising and manufacturing. Brian has a Bachelor of Business Administration from the University of Georgia, and he is a Certified Public Accountant (CPA).

Mr Tony Sommer, Jr.

Senior VP Sales and Marketing

Tony has 25 years of experience in sales and marketing management. Previously he served as Head of Sales for Bausch & Lomb’s US Vision Care division. A combat veteran, Tony holds a Bachelor of Science from the United States Air Force Academy and Master of Business Administration from Oklahoma City University.

Christi Van Heek

Non-executive Director

Christi has served as an adviser and consultant to several companies in the bio-pharmaceutical industry. From 1991 to 2003, Ms. van Heek served in various roles at Genzyme, Inc., a biotechnology company, including positions as Corporate Officer and President, Therapeutics Division; General Manager, Renal Division; and Vice President, Global Marketing. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA. Christi received a B.S.N. from the University of Iowa and holds a Master of Business Administration from Lindenwood University in St. Louis.

Jean Franchi

Non-executive Director

Jean has 20 years of experience building finance/accounting systems and teams in the life sciences industry.Currently she serves as CFO of Merrimack, a NASDAQ- listed pharmaceutical company and previously served as SVP Corporate Finance at Genzyme, a biotech company with over $4B in revenue, and as CFO of Dimension Therapeutics and Good Start Genetics

Zita Peach

Non-executive Director

With over 30 years of experience in the pharmaceutical, biotechnology, medical device & healthcare sectors, Zita currently serves on the board of ASX-listed Starpharma Holdings and Monash IVF Group, and has a board position with Bionic Vision Technologies Pty Ltd. Previously held executive roles at ASX-listed CSL Limited and Fresenius Kabi.

Tom Dooley

Non-executive Director

Tom has 30 years of experience in pharma and medical devices, including contact lenses and eye care. Most recently, he served as President of Alcon Japan, where he oversaw 1300 employees and $1B in revenue from contact lens products, medical devices, and pharma. Previously he served as Alcon’s country manager in Australia and New Zealand.

Andrew Silverberg

Non-executive Director

Andrew has over 20 years of experience as an investor and leader in the global money management industry.  Currently with Thorney Investment Group, Andrew possesses deep experience and relationships in investment management, capital markets, and investment banking, and has held impactful roles at Talpion Fund Management, Fred Alger Management and Mark Asset Management.  Andrew is a graduate of Brooklyn College with a Bachelor of Science degree in Business, Management and Finance.